Cipla Q2 FY27 results: Net profit declines 35% YoY; firm invests ₹423 crore in R&D

The pharma major’s total revenue from operations for the quarter under review stood at ₹7,404 crore, marking a fall of 2.4% from ₹7,589 crore reported in the second quarter of FY26.

For Q2 FY27, the company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) slipped 27% year-on-year (YoY) to ₹1,388 crore as against ₹1,894 crore reported in the same quarter of FY26.

Cipla’s margin for the reporting quarter also contracted to 18.75% in contrast to 24.96% YoY.

In Q2FY27, the pharma company delivered global revenues of ₹7,404 crore with a sequential growth of 4% QoQ, while EBITDA margin expanded by 200 basis points QoQ to 18.7%.

The company’s One-India business recorded its highest quarterly sales, registering a 12% year-on-year growth. In North America, its reported quarterly revenue of $172 million.

In One Africa, South Africa’s private business grew 1.3 times faster than the market. The Emerging Markets and Europe business recorded quarterly revenue of $101 million despite geopolitical uncertainties.

“Branded Prescription business delivered a robust growth, with key therapies outpacing the market. The US business posted revenue of $172 Mn during the quarter, continuing its sequential growth trajectory. We expect North America performance to remain supported by our upcoming product pipeline. South Africa private market business continued to outperform the market, growing approximately 1.3x faster than the market,” said Achin Gupta MD and Global CEO, Cipla.

Cipla invested ₹423 crore in research and development (R&D), accounting for 5.7% of sales, with investments directed largely towards product filings and key development programmes. The company reported a net cash position of ₹9,823 crore, with debt primarily comprising lease liabilities and working capital requirements.

“We continue to focus on sustained growth in our core businesses, improving productivity, strengthening our pipeline in order to serve patients with trusted, high-quality medicines,” said Gupta.

The trade generics business delivered a strong double-digit QoQ growth. Its expanded portfolio remains a key growth driver, with over 15 new launches this quarter, addressing specific patient needs.

Cipla share price trends

Following the earnings, Cipla shares were trading lower. At 1:30 PM, Cipla shares were trading at ₹1,336 apiece on the National Stock Exchange, declining 1.4%.

The stock has touched an intraday low of ₹1,334.70 per share after opening at ₹1,352.10 on Tuesday. Its day’s high was at ₹1,372.70 per share.

From the beginning of the year, Cipla shares have slipped 12%. Over a month’s time, the stock has fallen 4%, while it climbed 0.6% in the past six months.

Shares of the firm had hit a 52-week high of ₹1,593.80 on October 27, 2025, and a 52-week low of ₹1,165.70 on April 2, 2026.

According to NSE data, as of October 27, 2026, Cipla has a total market capitalisation of ₹1.08 lakh crore.